ACTIVE I (Ongoing)
Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events
Content currently under construction.
The purpose of this study is to determine if irbesartan 300mg once daily (od) compared to placebo tablet (an inert substance) will reduce the risk of vascular events such as heart attack, stroke, non-cerebral thromboembolic event and death during approximately 3 years of follow-up in patients with atrial fibrillation and with a systolic blood pressure of at least 110 mmHg associated with at least one major risk of vascular events because they are already enrolled into ACTIVE A or ACTIVE W study.
Study Design: Prevention, Randomized, Double Blind (Subject, Investigator), Placebo Control, Factorial Assignment, Efficacy Study
Length of Study: 6.5 years
# of Patients: 9000
Patient Populations: Atrial Fibrillation.
Publications (for a full listing of publications, please visit the 'Media and Publications' section)